For FAD2 + AZA2, the anti-proliferative effect in AML samples was significantly increased compared to both FAD2 and AZA2 (%Undivided %undivided of 68.7 ± 29.1% for FAD2 + AZA2 compared with 28.5 ± 10.2% in FAD2, p = 0.0004; and 33.5 ± 17% in AZA2, p = 0.0024), as well as NDC (Fig. 4C), indicating synergism of this combination with a combination index (CI) of 0.75. The gene discussed is FANCD2; the disease is acute myeloid leukemia.